RELATIONSHIP OF [H-3] ARA-C INCORPORATION AND RESPONSE TO THERAPY WITH HIGH-DOSE ARA-C IN AML PATIENTS - A LEUKEMIA INTERGROUP STUDY

被引：0

作者：

RAZA, A

GEZER, S

ANDERSON, J

LYKINS, J

BENNETT, J

BROWMAN, G

GOLDBERG, J

LARSON, R

VOGLER, R

PREISLER, HD

机构：

[1] NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, BUFFALO, NY 14263 USA

[2] HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA

[3] UNIV ROCHESTER, ROCHESTER, NY 14627 USA

[4] HAMILTON CIV HOSP, HAMILTON, ONTARIO, CANADA

[5] HLTH SCI CTR SYRACUSE, SYRACUSE, NY USA

[6] UNIV CHICAGO, MED CTR, CHICAGO, IL 60637 USA

[7] EMORY UNIV, ATLANTA, GA 30322 USA

来源：

EXPERIMENTAL HEMATOLOGY | 1992年 / 20卷 / 10期

关键词：

ACUTE MYELOID LEUKEMIA; CYTOSINE ARABINOSIDE; DRUG SENSITIVITY; REMISSION OUTCOME;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pretherapy bone mar-row (BM) aspirates of 143 patients with acute myeloid leukemia (AML) were incubated simultaneously with bromodeoxyuridine (BrdU) and tritiated cytosine arabinoside ([H-3]Ara-C) to determine the labeling index (LI) and extent of [H-3]Ara-C incorporation. Of 143 AML patients, 121 received high-dose Ara-C (HDAra-C) as a single agent for induction therapy (55 newly diagnosed, 66 in first relapse), whereas 22 received HDAra-C plus mAMSA. The data demonstrate that a subset of patients who will fail HDAra-C remission induction therapy because of drug-resistant disease can be prospectively identified on the basis of the low amount of Ara-C incorporated by their leukemia cells.

引用

页码：1194 / 1200

页数：7

共 50 条

[31] SUBACUTE PULMONARY FAILURE COMPLICATING THERAPY WITH HIGH-DOSE ARA-C IN ACUTE-LEUKEMIA
ANDERSSON, BS
COGAN, BM
KEATING, MJ
ESTEY, EH
MCCREDIE, KB
FREIREICH, EJ
CANCER, 1985, 56 (09) : 2181 - 2184
[32] TREATMENT OF POOR RISK LEUKEMIA IN CHILDREN WITH HIGH-DOSE ARA-C AND ASPARAGINASE (HD-ARA-C-ASNASE)
GRUMAYER, ER
SCHMIDMEIER, W
GADNER, H
BLUT, 1985, 51 (03): : 209 - 209
[33] ALTERATION OF THE PHARMACOKINETICS OF HIGH-DOSE ARA-C BY ITS METABOLITE, HIGH ARA-U IN PATIENTS WITH ACUTE-LEUKEMIA
CAPIZZI, RL
YANG, JL
CHENG, E
BJORNSSON, T
SAHASRABUDHE, D
TAN, RS
CHENG, YC
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (12) : 763 - 771
[34] SMALL DOSE ARA-C THERAPY - RESULTS IN SELECTED PATIENTS WITH SMOULDERING LEUKEMIA
SCHLAG, R
THIEL, E
MAHL, G
ONKOLOGIE, 1983, 6 (05): : 226 - 226
[35] PHARMACOKINETICS OF HIGH-DOSE CYTOSINE-ARABINOSIDE (ARA-C)
HANDE, KR
STEIN, RS
MCDONOUGH, DA
WOLFF, SN
CLINICAL RESEARCH, 1981, 29 (02): : A436 - A436
[36] INTERMEDIATE-DOSE ARA-C AND IDARUBICIN FOLLOWED BY LOW-DOSE ARA-C IS PARTICULARLY EFFECTIVE IN UNMAINTAINED RELAPSED AML
MUUS, P
DEWITTE, T
RAEMAEKERS, J
BLOOD, 1994, 84 (10) : A146 - A146
[37] SEQUENTIAL HIGH-DOSE ARA-C AND ASPARAGINASE IN THE THERAPY OF PREVIOUSLY TREATED AND UNTREATED PATIENTS WITH ACUTE-LEUKEMIA
CAPIZZI, RL
POWELL, BL
COOPER, MR
STUART, JJ
MUSS, HB
RICHARDS, F
JACKSON, DV
WHITE, DR
SPURR, CL
ZEKAN, PJ
CRUZ, JM
CRAIG, JB
SEMINARS IN ONCOLOGY, 1985, 12 (02) : 105 - 113
[38] Dose escalation of ara-C may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-α and low-dose ara-C
Hilbe, W
Kühr, T
Apfelbeck, U
Fridrik, M
Seewann, H
Stöger, M
Linkesch, W
Pont, J
Baldinger, C
Hartner, E
Bernhart, M
Geissler, D
Krieger, O
Lang, A
Lin, W
Ludwig, H
Duba, C
Greil, R
Gastl, G
Thaler, J
LEUKEMIA & LYMPHOMA, 2001, 42 (06) : 1283 - 1288
[39] High dose ara-C as upfront therapy for adult patients with acute lymphoblastic leukemia (ALL).
Hallbook, H
Simonsson, B
Bjorkholm, M
Braide, I
Carneskog, J
Grimfors, G
Hast, R
Karlsson, R
Kimby, E
Lerner, R
Linder, O
Linderholm, M
Lofvenberg, E
Malm, PG
Nilsson, PG
Paul, C
Petrescu, A
Rodjer, S
Tidefelt, U
Turesson, I
Uden-Blohme, AM
Vilen, L
Winquist, I
Zettervall, O
Smedmyr, B
BLOOD, 1999, 94 (10) : 297A - 297A
[40] DETECTION AND QUANTITATION OF ARA-C 5'-TRIPHOSPHATE (ARA-CTP) IN THE LEUKEMIC-CELLS OF ADULT AML PATIENTS TREATED WITH ARA-C
HUG, V
PLUNKETT, W
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 373 - 373

← 1 2 3 4 5 →